**Core Concept:**
Hepatitis B virus (HBV) infection can be classified into several phases based on serology markers and liver enzyme levels, including HBsAg positivity, HBeAg status, and normal ALT/AST. The next step in management depends on the clinical context and disease stage.

**Why the Correct Answer is Right:**
In this case, the patient is a 26-year-old man with HBsAg positivity and normal ALT/AST levels, but HBeAg negativity. This patient is in the immune-tolerant phase of chronic hepatitis B infection, where the immune system is unable to control the virus effectively but the liver enzymes remain normal. In this phase, the focus is on preventing the development of liver disease, which is why the next step in management is to initiate antiviral therapy to suppress HBV replication, reduce viral load, and prevent liver damage.

**Why Each Wrong Option is Incorrect:**
A. This option does not consider the patient's HBeAg status and focuses solely on enzyme levels, which is not relevant in this case.
B. This option focuses on enzyme levels, ignoring the patient's HBsAg positivity and HBeAg negativity, which are crucial factors in determining the management approach.
C. This option does not address the patient's immune status and enzyme levels, leading to an incorrect management plan.
D. This option focuses on enzyme levels, not considering the patient's HBsAg positivity and HBeAg negativity, leading to an incorrect management approach.

**Clinical Pearl:**
In chronic hepatitis B infection, understanding the serological markers (HBsAg, HBeAg, anti-HBe) and liver enzyme levels is essential for determining the phase of infection and selecting the appropriate management strategy. In this case, initiating antiviral therapy is crucial for preventing liver disease progression, as the patient is in the immune-tolerant phase with normal liver enzymes.